-
Sector Analysis
NewIdiopathic Hypersomnia (IH) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Idiopathic Hypersomnia (IH) Marketed and Pipeline Drugs Report Overview Idiopathic Hypersomnia (IH) is a rare chronic sleep disorder with the primary complaint being the irresistible need to sleep and waking up non-refreshed despite the prolonged duration of sleep, for at least three months. IH belongs to the primary sleep disorder category of hypersomnia. Primary hypersomnia includes narcolepsy type 1 and type 2, and Kleine-Levin syndrome, which commonly occurs in teenage males along with IH. Key Mechanism of Action (Marketed) ·      ...
-
Product Insights
NewSocial Anxiety Disorder (SAD/Social Phobia) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Social Anxiety Disorder (SAD/Social Phobia) Clinical Trials Market Report Overview The social anxiety disorder (SAD/social phobia) trial market research report provides an overview of the social anxiety disorder (SAD/social phobia) trials scenario. The report provides top-line data relating to the clinical trials on social anxiety disorder. It also includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase,...
-
Product Insights
NewArthralgia (Joint Pain) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Arthralgia (Joint Pain) Clinical Trials Market Report Overview The arthralgia (joint pain) clinical trial market research report provides an overview of the arthralgia (joint pain) clinical trials scenario. The report provides top-line data relating to the clinical trials on arthralgia (joint pain). It also includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points...
-
Product Insights
NewAutism Spectrum Disorder (ASD) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Autism Spectrum Disorder (ASD) Clinical Trials Market Report Overview The Autism Spectrum Disorder (ASD) clinical trial market research report provides an overview of the Autism Spectrum Disorder (ASD) clinical trials scenario. This report provides top-line data relating to the clinical trials on ASD and includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report also offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...
-
Sector Analysis
NewSpinal Muscular Atrophy (SMA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Spinal Muscular Atrophy (SMA) Marketed and Pipeline Drugs Report Overview Spinal muscular atrophy (SMA) is a group of clinically and genetically heterogenous inherited neuromuscular disorders characterized by the loss of lower motor neurons in the spinal cord, resulting in progressive muscle weakness, muscle wasting, and low muscle tone. However, neurons controlling most voluntary muscles like those involved in feeding, swallowing, and breathing can also be affected. Key Mechanism of Action (Marketed) ·      Protein or Peptide Activator ·      Receptor Agonist Key...
-
Sector Analysis
Post-Traumatic Stress Disorder (PTSD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Post-Traumatic Stress Disorder (PTSD) Marketed and Pipeline Drugs Overview In the seven major pharmaceutical markets (7MM: France, Germany, Italy, Japan, Spain, UK and the US), GlobalData epidemiologists estimated more than 1.02 million acute diagnosed prevalent cases for PTSD in 2023. Post-Traumatic Stress Disorder (PTSD) is a mental disorder that can occur after experiencing a traumatic event. Characterized by symptoms typical of anxiety disorders such as irritability, sleep disturbances, disrupted concentration, and increased heart rate, PTSD is distinguished by the patient...
-
Product Insights
Cerebral Palsy Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Cerebral Palsy Clinical Trials Market Report Overview The Cerebral Palsy clinical trial market research report provides an overview of the Cerebral Palsy Clinical trials scenario. This report provides top-line data relating to the clinical trials on Cerebral Palsy and an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report also offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type. It...
-
Sector Analysis
Autism Spectrum Disorder (ASD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Autism Spectrum Disorder (ASD) Marketed and Pipeline Drugs Report Overview Autism, or autism spectrum disorder (ASD), refers to a broad range of conditions characterized by challenges with social skills, repetitive behaviors, speech, and nonverbal communication. ASD is a neurological and developmental disorder that affects how people interact with others, communicate, learn, and behave. As ASD is a spectrum disorder, each person with ASD has a distinct set of strengths and challenges. The ways in which people with ASD learn, think,...
-
Sector Analysis
Parkinson’s Disease in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast 2029
Parkinson’s Disease Market Overview Parkinson’s Disease market size across the 7MM was valued at $3.4 billion in 2019 and is expected to achieve a CAGR of more than 6% during 2019-2029. The US is the most significant contributor to that revenue mainly due to the cost of drugs, which is significantly higher in the US compared to other countries in the 7MM. Parkinson’s Disease Market Outlook, 2019-2029 ($ Billion) To gain more information on the Parkinson’s Disease market forecast, download...
-
Sector Analysis
Alcohol Use Disorder (AUD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Alcohol Use Disorder (AUD) Marketed and Pipeline Drugs Report Overview Alcohol use disorder (AUD) is a medical condition characterized by an impaired ability to stop or control alcohol use despite adverse social, occupational, or health consequences. It encompasses the conditions that some people refer to as alcohol abuse, alcohol dependence, alcohol addiction, and the colloquial term, alcoholism. Although the pathogenesis of AUD is not fully known, several factors are thought to contribute to its development, such as biological, environmental, social, psychological,...
-
Product Insights
Schizophrenia Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Schizophrenia Clinical Trials Market Report Overview The Schizophrenia clinical trial market research report provides an overview of the Schizophrenia Clinical trials scenario. This report provides top-line data relating to the clinical trials on Schizophrenia and includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report also offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type. It provides prominent drugs...
-
Product Insights
Tourette Syndrome Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Tourette Syndrome Clinical Trials Market Report Overview The Tourette Syndrome clinical trial market research report provides an overview of the Tourette Syndrome Clinical trials scenario. This report provides top-line data relating to the clinical trials on Tourette Syndrome and includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report also offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type....
-
Sector Analysis
Narcolepsy Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Narcolepsy Marketed and Pipeline Drugs Report Overview Narcolepsy is a chronic disorder that is mainly characterized by excessive daytime sleepiness and, in the majority of individuals, cataplexy—a sudden loss of muscle tone during wakefulness that is evoked by strong, usually positive, emotions. Patients with narcolepsy can also experience disturbed nighttime sleep, sleep paralysis, hypnagogic hallucinations, or hypnopompic hallucinations. Narcolepsy marketed and pipeline drugs market research report report includes an assessment of the disease epidemiology, leading marketed products with sales forecast,...
-
Sector Analysis
Chronic Low Back Pain (CLBP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
CLBP Marketed and Pipeline Drugs Report Overview Chronic low back pain (CLBP) is defined as pain that continues for 12 weeks or longer, even after an initial injury or underlying cause of acute low back pain (BP) has been treated. It represents the second-leading cause of disability worldwide and is a major health and economic problem. CLBP is a complex disease with high heterogeneity and is increasingly dubbed a mixed pain syndrome with neuropathic and injurious components. CLBP develops in...
-
Product Insights
Post-Traumatic Stress Disorder Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Post-Traumatic Stress Disorder (PTSD) Clinical Trials Market Report Overview The PTSD clinical trial market research report provides an overview of PTSD clinical trials scenario. This report provides top line data relating to the clinical trials on PTSD. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The...
-
Product Insights
Dementia Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Dementia Clinical Trials Market Overview The dementia clinical trial market research report provides an overview of Dementia Clinical trials scenario. This report provides top line data relating to the clinical trials on Dementia. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides prominent...
-
Sector Analysis
Alzheimer’s Disease Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2030
Alzheimer’s Disease Market Report Overview Alzheimer’s Disease and MCI market size across the 8MM was valued at $2.2 billion in 2020 and is expected to achieve a CAGR of more than 19% during 2020-2030. AD is a progressive neurodegenerative disease that is characterized by memory loss, cognitive impairment, and functional decline. Mild cognitive impairment (MCI) is a phase of the AD continuum in which a gradually progressive cognitive decline occurs and may even become clinically relevant. Alzheimer’s Disease Market Outlook,...
-
Sector Analysis
Lewy Body Dementia (LBD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Lewy Body Dementia (LBD) Marketed and Pipeline Drugs Report Overview Lewy body dementia (LBD) is a common type of dementia that happens when clumps of proteins called Lewy bodies build up in the brain. They damage parts of the brain that affect cognition, behavior, movement, and sleep. Lewy body intracellular inclusions result from the aggregation of misfolded α-synuclein. There will be more than 1.1 million diagnosed prevalent cases of LBD in 2023 in the 16 countries covered in GlobalData’s epidemiology...
-
Sector Analysis
Body Dysmorphic Disorder (BDD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Body Dysmorphic Disorder Clinical Trials Report Overview Body dysmorphic disorder (BDD), also known as dysmorphophobia, is a severe psychiatric condition in which an individual spends a significant amount of time worrying about flaws in their own or another person’s appearance. These flaws are frequently overlooked by others. BDD can affect people of any age, but it is most common in teenagers and young adults. It affects both men and women. The BDD marketed and pipeline drugs market research report includes...
-
Product Insights
Obsessive-Compulsive Disorder Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Obsessive-Compulsive Disorder Clinical Trials Market Report Overview The Obsessive-Compulsive Disorder clinical trial market research report provides an overview of the Obsessive-Compulsive Disorder clinical trials scenario. The report provides top-line data relating to the clinical trials on Obsessive-Compulsive Disorder. It also includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type....
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.